Fairvalue-Calculator Fairvalue-Calculator
EN DE

AI Maverick Intel, Inc (AIMV) Fair Value & Analysis

Healthcare · US · Market cap $13.0M

Price$0.1300
Fair Value$0.0200
Upside-84.6%
Quality95/100
Evidence: Low Range $0.0100 – $0.0300

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

AI Maverick Intel, Inc (AIMV) currently trades at $0.1300, while our model-based Fair Value estimate is $0.0200 — implying the stock looks roughly 84.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

AI Maverick Intel, Inc., an AI company, focuses on acquiring and enhancing businesses through its proprietary AI Maverick platform. Its technology streamlines the customer acquisition process by automating two way communication and data-driven engagement with its clients ideal audience segments across healthcare, biotech, and other sectors. The company was formerly known as Bionoid Pharma Inc. and changed its name to AI Maverick Intel, Inc. in April 2025. AI Maverick Intel, Inc. was incorporated in 2006 and is based in Beverly Hills, California.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is AI Maverick Intel, Inc (AIMV) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0200 versus a price of $0.1300 — about −85% (overvalued). Model-based estimate, not financial advice.
What is the fair value of AIMV?
Our 21-model fair value for AI Maverick Intel, Inc is $0.0200 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.1300.
What is the quality score of AIMV?
AI Maverick Intel, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.